Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
Finance
AstraZeneca investors raise concerns over mega-merger talks
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
Anchor News
- 1 min read
Related
More FinanceFinanceOriginal
Traders in the world’s most important financial market are bracing for a wild stretch ahead
Anchor News-